 TARRYTOWN, NY, Nov. 22, 2022 GLOBE NEWSWIRE -- via NewMediaWire PaxMedica, Inc. Nasdaq: PXMD, a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies APT for the treatment of disorders with intractable neurologic symptoms, today announced it will be presenting at the Benchmark Companys 11th Annual Discovery One-on-One Investor Conference to be held Thursday, December 1st, 2022 at the New York Athletic Club in New York City. 